Research
Hormonal
GLP-1 receptor agonists (e.g., Liraglutide 3.0mg) and SGLT2 inhibitors significantly reduce body weight and improve glycemic control in T2D patients, with GLP-1 agonists showing superior weight loss compared to other drug classes.
If lifestyle changes are not enough, ask your doctor about GLP-1 receptor agonists (like Liraglutide) or SGLT2 inhibitors. These drugs help you lose weight and control blood sugar, unlike older diabetes medications that cause weight gain. GLP-1s are particularly effective for weight loss.
StrongSupportsVERY_HIGH confidence
Агонисты рецепторов ГПП-1... ассоциируются со значительным снижением массы тела... Ингибиторы натрий-глюкозных котранспортеров 2 типа (НГЛТ-2)... способствуют выведению из организма калорий, что приводит к снижению веса на 2 кг в среднем
Why this rating
Based on multiple RCTs and meta-analyses cited (SCALE, LEADER, EMPAREG-OUTCOME, CANVAS).
Source
Obesity and type 2 diabetes: can we find a compromised treatment solution?
G. R. Galstyan et al. · Diabetes Mellitus · 2017
DOI 10.14341/dm8726
narrative_reviewCited 18×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Intensive lifestyle interventions (caloric restriction and physical activity) can induce significant weight loss (5-10%) and improve glycemic control in type 2 diabetes, but long-term maintenance is difficult due to physiological counter-regulation (increased appetite/hormonal resistance).Good
- Insulin and Sulfonylureas cause weight gain in T2D patients, which exacerbates insulin resistance and creates a cycle requiring further treatment intensification.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →